<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>hiv aids</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>hiv aids | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review
Authors: Chu, C.; Tao, K.; Kouamou, V.; Avalos, A.; Scott, J.; Grant, P. M.; Rhee, S.-Y.; McCluskey, S. M.; Jordan, M. R.; Morgan, R. L.; Shafer, R. W.
Score: 2.2, Published: 2024-01-07 DOI: 10.1101/2024.01.05.24300911
BackgroundDolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of virological failure (VF) with emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/hiv-aids/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="hiv aids" />
<meta property="og:description" content="Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review
Authors: Chu, C.; Tao, K.; Kouamou, V.; Avalos, A.; Scott, J.; Grant, P. M.; Rhee, S.-Y.; McCluskey, S. M.; Jordan, M. R.; Morgan, R. L.; Shafer, R. W.
Score: 2.2, Published: 2024-01-07 DOI: 10.1101/2024.01.05.24300911
BackgroundDolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of virological failure (VF) with emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/hiv-aids/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2024-01-21T10:39:08+00:00" />
<meta property="article:modified_time" content="2024-01-21T10:39:08+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="hiv aids"/>
<meta name="twitter:description" content="Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review
Authors: Chu, C.; Tao, K.; Kouamou, V.; Avalos, A.; Scott, J.; Grant, P. M.; Rhee, S.-Y.; McCluskey, S. M.; Jordan, M. R.; Morgan, R. L.; Shafer, R. W.
Score: 2.2, Published: 2024-01-07 DOI: 10.1101/2024.01.05.24300911
BackgroundDolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of virological failure (VF) with emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "hiv aids",
      "item": "https://trxiv.yorks0n.com/posts/hiv-aids/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "hiv aids",
  "name": "hiv aids",
  "description": "Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review\nAuthors: Chu, C.; Tao, K.; Kouamou, V.; Avalos, A.; Scott, J.; Grant, P. M.; Rhee, S.-Y.; McCluskey, S. M.; Jordan, M. R.; Morgan, R. L.; Shafer, R. W.\nScore: 2.2, Published: 2024-01-07 DOI: 10.1101/2024.01.05.24300911\nBackgroundDolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of virological failure (VF) with emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART.",
  "keywords": [
    
  ],
  "articleBody": " Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review\nAuthors: Chu, C.; Tao, K.; Kouamou, V.; Avalos, A.; Scott, J.; Grant, P. M.; Rhee, S.-Y.; McCluskey, S. M.; Jordan, M. R.; Morgan, R. L.; Shafer, R. W.\nScore: 2.2, Published: 2024-01-07 DOI: 10.1101/2024.01.05.24300911\nBackgroundDolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of virological failure (VF) with emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART. MethodsWe performed a PubMed search using the term \"Dolutegravir\" last updated December 18, 2023, to estimate the prevalence of VF with emergent INSTI DRMs in clinical trials and cohorts of people living with HIV (PLWH) without previous VF on an INSTI who received DTG-containing ART. ResultsOf 2131 records identified by search, 43 clinical trials, 39 cohorts, and six cross-sectional studies provided data across six clinical scenarios based upon ART history, virological status, and ARVs co-administered with DTG: (1) ART-naive PLWH receiving DTG plus two nucleoside reverse transcriptase inhibitors (NRTIs); (2) ART-naive PLWH receiving DTG plus lamivudine; (3) ART-experienced PLWH with VF on their previous regimen receiving DTG plus two NRTIs; (4) ART-experienced PLWH with virological suppression receiving DTG plus two NRTIs; (5) ART-experienced PLWH with virological suppression receiving DTG and a second ARV; and (6) ART-experienced PLWH with virological suppression receiving DTG monotherapy. The proportion of PLWH in clinical trials with emergent INSTI DRMs was 1.6% for scenario 3 and 2.9% for scenario 6. In the remaining four trial scenarios, prevalence of VF with emergent INSTI DRMs was [\u0026le;]0.1%. Data from cohort studies minimally influenced prevalence estimates from clinical trials, while cross-sectional studies yielded prevalence data lacking denominator details. ConclusionsIn clinical trials, the prevalence of VF with emergent INSTI DRMs in PLWH receiving DTG-containing regimens has been low. Novel approaches are required to assess the risk of VF with emergent INSTI DRMs in PLWH receiving DTG in real-world settings. What is already known on this topicDolutegravir is known for its high resistance barrier, yet there remains a concern for virological failure and subsequent drug resistance in people living with HIV who begin first or second-line antiretroviral therapy with a dolutegravir-containing regimen. What this study addsThe prevalence of virological failure with the development of HIV mutations associated with reduced susceptibility to dolutegravir depends on a persons virological response to previous antiretroviral therapy, the presence of HIV replication at dolutegravir initiation, and the antiretroviral drugs co-administered with dolutegravir. In clinical trial settings, the prevalence of virological failure with emergent dolutegravir resistance was rare among people initiating therapy with a dolutegravir-containing regimen and was 1.6% over a period of one to two years among those who had previously experienced virological failure on an earlier treatment regimen. In the subset of persons with virological failure on a first-line dolutegravir-containing regimen, the prevalence of emergent dolutegravir resistance was 0.7%, whereas in the subset of persons with virological failure on a second-line dolutegravir-containing regimen, the prevalence of emergent dolutegravir resistance was 20.4%. How this study might affect research, practice, or policyIn people living with HIV with virological failure on a first-line dolutegravir-containing regimen, enhancing medication adherence may prove more beneficial than transitioning to an alternative treatment regimen. In cases of virological failure on a second-line dolutegravir-containing regimen, the potential for dolutegravir resistance suggests a need to investigate the role of genotypic resistance testing to inform treatment changes. Population-level surveillance for acquired dolutegravir resistance should take into account the antiretroviral treatment history and level of HIV replication prior to the initiation of dolutegravir-containing therapy.\nEvaluation of four interventions using behavioural economics insights to increase demand for voluntary medical male circumcision in South Africa through the MoyaApp: A quasi-experimental study\nAuthors: Mistri, P.; Tomescu, S. M.; Bokolo, S. S.; de Nooy, A.; Pisa, P.; Grove, S.; Schmucker, L.; Chetty-Makkan, C. M.; Long, L.; Buttenheim, A.; Maughan-Brown, B.\nScore: 0.5, Published: 2024-01-20 DOI: 10.1101/2024.01.18.24301032\nBackground Voluntary medical male circumcision (VMMC) reduces the risk of HIV transmission by 60%, however, circumcision coverage falls short of the UNAIDS 90% target. We investigated whether behaviourally informed message framing increased demand for VMMC. Setting We included adult users of a data free application in South Africa, the MoyaApp, who viewed a form designed to generate interest in VMMC during August-November 2022. Methods A quasi-experimental study was conducted to evaluate four MoyaApp VMMC intervention forms against the Standard of Care (SOC) form. The primary outcome was the proportion of form submissions in which users provided their contact details for further engagement. Secondary outcomes included successful contact with the user, VMMC bookings/referrals and confirmed circumcision. Chi-squared tests and ordinary least-squares regressions were used for the analysis. Results MoyaApp VMMC form viewers totalled 118,337 of which 6% submitted a form. Foot -in-the-Door form viewers were more likely (+1.3 percentage points, p\u003c0.01) to submit a form compared to the SOC group (6.3%). Active Choice (-1.1 percentage points, p\u003c0.01) and Reserved for You (-0.05 percentage points, p\u003c0.05) form viewers were less likely to submit a form compared to SOC. Users submitting on Foot-in-the-Door were less likely to be booked/referred compared to SOC (-5 percentage points, p\u003c0.05). There were no differences between the intervention and SOC forms for successful contact and circumcisions. Conclusions Message framing using behavioural insights was able to nudge men to engage with VMMC services, however, more work is needed to understand how to convert initial interest into bookings and circumcisions.\n",
  "wordCount" : "909",
  "inLanguage": "en",
  "datePublished": "2024-01-21T10:39:08Z",
  "dateModified": "2024-01-21T10:39:08Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/hiv-aids/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      hiv aids
    </h1>
    <div class="post-meta">&lt;span&gt;updated on January 21, 2024&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.05.24300911">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.05.24300911" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.05.24300911">
        <p class="paperTitle">Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.05.24300911" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.05.24300911" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Chu, C.; Tao, K.; Kouamou, V.; Avalos, A.; Scott, J.; Grant, P. M.; Rhee, S.-Y.; McCluskey, S. M.; Jordan, M. R.; Morgan, R. L.; Shafer, R. W.</p>
        <p class="info">Score: 2.2, Published: 2024-01-07 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.05.24300911' target='https://doi.org/10.1101/2024.01.05.24300911'> 10.1101/2024.01.05.24300911</a></p>
        <p class="abstract">BackgroundDolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of virological failure (VF) with emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART.

MethodsWe performed a PubMed search using the term &#34;Dolutegravir&#34; last updated December 18, 2023, to estimate the prevalence of VF with emergent INSTI DRMs in clinical trials and cohorts of people living with HIV (PLWH) without previous VF on an INSTI who received DTG-containing ART.

ResultsOf 2131 records identified by search, 43 clinical trials, 39 cohorts, and six cross-sectional studies provided data across six clinical scenarios based upon ART history, virological status, and ARVs co-administered with DTG: (1) ART-naive PLWH receiving DTG plus two nucleoside reverse transcriptase inhibitors (NRTIs); (2) ART-naive PLWH receiving DTG plus lamivudine; (3) ART-experienced PLWH with VF on their previous regimen receiving DTG plus two NRTIs; (4) ART-experienced PLWH with virological suppression receiving DTG plus two NRTIs; (5) ART-experienced PLWH with virological suppression receiving DTG and a second ARV; and (6) ART-experienced PLWH with virological suppression receiving DTG monotherapy. The proportion of PLWH in clinical trials with emergent INSTI DRMs was 1.6% for scenario 3 and 2.9% for scenario 6. In the remaining four trial scenarios, prevalence of VF with emergent INSTI DRMs was [&amp;le;]0.1%. Data from cohort studies minimally influenced prevalence estimates from clinical trials, while cross-sectional studies yielded prevalence data lacking denominator details.

ConclusionsIn clinical trials, the prevalence of VF with emergent INSTI DRMs in PLWH receiving DTG-containing regimens has been low. Novel approaches are required to assess the risk of VF with emergent INSTI DRMs in PLWH receiving DTG in real-world settings.

What is already known on this topicDolutegravir is known for its high resistance barrier, yet there remains a concern for virological failure and subsequent drug resistance in people living with HIV who begin first or second-line antiretroviral therapy with a dolutegravir-containing regimen.

What this study addsThe prevalence of virological failure with the development of HIV mutations associated with reduced susceptibility to dolutegravir depends on a persons virological response to previous antiretroviral therapy, the presence of HIV replication at dolutegravir initiation, and the antiretroviral drugs co-administered with dolutegravir.

In clinical trial settings, the prevalence of virological failure with emergent dolutegravir resistance was rare among people initiating therapy with a dolutegravir-containing regimen and was 1.6% over a period of one to two years among those who had previously experienced virological failure on an earlier treatment regimen.

In the subset of persons with virological failure on a first-line dolutegravir-containing regimen, the prevalence of emergent dolutegravir resistance was 0.7%, whereas in the subset of persons with virological failure on a second-line dolutegravir-containing regimen, the prevalence of emergent dolutegravir resistance was 20.4%.

How this study might affect research, practice, or policyIn people living with HIV with virological failure on a first-line dolutegravir-containing regimen, enhancing medication adherence may prove more beneficial than transitioning to an alternative treatment regimen.

In cases of virological failure on a second-line dolutegravir-containing regimen, the potential for dolutegravir resistance suggests a need to investigate the role of genotypic resistance testing to inform treatment changes.

Population-level surveillance for acquired dolutegravir resistance should take into account the antiretroviral treatment history and level of HIV replication prior to the initiation of dolutegravir-containing therapy.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.18.24301032">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.18.24301032" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.18.24301032">
        <p class="paperTitle">Evaluation of four interventions using behavioural economics insights to increase demand for voluntary medical male circumcision in South Africa through the MoyaApp: A quasi-experimental study</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.18.24301032" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.18.24301032" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Mistri, P.; Tomescu, S. M.; Bokolo, S. S.; de Nooy, A.; Pisa, P.; Grove, S.; Schmucker, L.; Chetty-Makkan, C. M.; Long, L.; Buttenheim, A.; Maughan-Brown, B.</p>
        <p class="info">Score: 0.5, Published: 2024-01-20 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.18.24301032' target='https://doi.org/10.1101/2024.01.18.24301032'> 10.1101/2024.01.18.24301032</a></p>
        <p class="abstract">Background Voluntary medical male circumcision (VMMC) reduces the risk of HIV transmission by 60%, however, circumcision coverage falls short of the UNAIDS 90% target. We investigated whether behaviourally informed message framing increased demand for VMMC. Setting We included adult users of a data free application in South Africa, the MoyaApp, who viewed a form designed to generate interest in VMMC during August-November 2022. Methods A quasi-experimental study was conducted to evaluate four MoyaApp VMMC intervention forms against the Standard of Care (SOC) form. The primary outcome was the proportion of form submissions in which users provided their contact details for further engagement. Secondary outcomes included successful contact with the user, VMMC bookings/referrals and confirmed circumcision. Chi-squared tests and ordinary least-squares regressions were used for the analysis. Results MoyaApp VMMC form viewers totalled 118,337 of which 6% submitted a form. Foot -in-the-Door form viewers were more likely (&#43;1.3 percentage points, p&lt;0.01) to submit a form compared to the SOC group (6.3%). Active Choice (-1.1 percentage points, p&lt;0.01) and Reserved for You (-0.05 percentage points, p&lt;0.05) form viewers were less likely to submit a form compared to SOC. Users submitting on Foot-in-the-Door were less likely to be booked/referred compared to SOC (-5 percentage points, p&lt;0.05). There were no differences between the intervention and SOC forms for successful contact and circumcisions. Conclusions Message framing using behavioural insights was able to nudge men to engage with VMMC services, however, more work is needed to understand how to convert initial interest into bookings and circumcisions.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2024 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
